Avidity Biosciences (RNA) Stock Price, News & Analysis

Company Overview

Avidity Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing genetic medicines for diseases that have historically been difficult to treat with conventional approaches. The company’s technology platform, known as Antibody Oligonucleotide Conjugates (AOCs), combines the targeting capabilities of antibodies with oligonucleotide-based medicines designed to act on RNA inside specific cells.

Avidity’s research programs are primarily directed at serious muscle diseases, including myotonic dystrophy type 1, facioscapulohumeral muscular dystrophy and Duchenne muscular dystrophy. Its pipeline has included delpacibart etedesiran, also known as AOC 1001, an investigational therapy designed to deliver an oligonucleotide to skeletal and cardiac muscle for the treatment of myotonic dystrophy type 1. The company is also advancing additional AOC-based candidates intended to address genetic disorders affecting muscle tissue.

Founded in 2012 and headquartered in San Diego, California, Avidity conducts discovery, development and clinical-stage activities primarily in the United States. The company’s programs remain investigational, and its AOC platform is intended to expand the range of tissues that can be reached by RNA-targeting medicines. Sarah Boyce serves as Avidity Biosciences’ president and chief executive officer.

Key Stats

• Today's Range: $8.13 to $8.50
• 50-Day Range: $7.84 to $14.60
• 52-Week Range: $7.63 to $16.77
• Volume: 208,346 shs
• Average Volume: 384,311 shs
• Market Capitalization: $143.69 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $63.75
• Consensus Rating: Hold

Avidity Biosciences Stock Analysis - MarketRank™

Avidity Biosciences scored higher than 41% of companies evaluated by MarketBeat, and ranked 754th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Hold

Consensus Rating

Avidity Biosciences has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 strong buy rating, 3 buy ratings, 11 hold ratings, and 1 sell rating.

Upside Potential

Avidity Biosciences has a consensus price target of $63.75, representing about 658.9% upside from its current price of $8.40.

Amount of Analyst Coverage

Avidity Biosciences has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Avidity Biosciences are expected to decrease in the coming year, from ($5.08) to ($8.11) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Avidity Biosciences is -3.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Avidity Biosciences is -3.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

20.64% of the float of Avidity Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Avidity Biosciences has a short interest ratio ("days to cover") of 8.27.

Change versus previous month

Short interest in Avidity Biosciences has recently decreased by 0.06%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Avidity Biosciences does not currently pay a dividend.

Dividend Growth

Avidity Biosciences does not have a long track record of dividend growth.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 0.37

News Sentiment

Avidity Biosciences has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Avidity Biosciences this week, compared to 3 articles on an average week.

Search Interest

4 people have searched for RNA on MarketBeat in the last 30 days.

MarketBeat Follows

3 people have added Avidity Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Avidity Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

3.83% of the stock of Avidity Biosciences is held by insiders.

Percentage Held by Institutions

Avidity Biosciences has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 10/10/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:RNA
• CIK: 1599901
• Web: www.aviditybiosciences.com
• Phone: 858-401-7900
• Fax: N/A
• Employees: 190
• Year Founded: 2013

Price Target and Rating

• Average Price Target for Avidity Biosciences: $63.75
• High Price Target: $74.00
• Low Price Target: $25.00
• Potential Upside/Downside: +658.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.25
• Research Coverage: 16 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.73
• Quick Ratio: 8.73

Sales & Book Value

• Annual Sales: $35.84 million
• Price / Sales: 4.01
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 17,106,000
• Free Float: 16,451,000
• Market Cap: $143.69 million
• Optionable: Optionable
• Beta: N/A